Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176030 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL176031 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL174674 | 0.86 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL174426 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL170964 | 0.82 | XDH (0.44) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL173905 | 0.79 | DGAT1 (0.52) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL174791 | 0.79 | CPT1A (0.42) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL162844 | 0.77 | CYP3A4 (0.40) | ALDH1A1SMN1; SMN2DGAT1CSNK2A1TRPV1 | |
| SCHEMBL173898 | 0.76 | MAPT (0.49) | SLC6A2SLC6A4SLC6A3XDHCPT1A | |
| SCHEMBL174413 | 0.72 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3XDHCPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | SLC6A2 449/4885SLC6A4 1375/4885SLC6A3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.